MitoQ trial targets MS fatigue – a new hope for tired patients?

NCT ID NCT04267926

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether MitoQ, a dietary supplement, can reduce fatigue in people with multiple sclerosis. 45 participants took either 20 mg, 40 mg, or a placebo daily for 12 weeks. Researchers measured changes in fatigue using a standard survey. The goal is to find a safe, simple way to improve daily energy for MS patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MitoQ (mitoquinone)

What this could lead to

If it works, this could offer a new option to help manage fatigue in people with multiple sclerosis.

What could go wrong

This is an early-phase trial with only 45 participants, so results may not apply to everyone. Fatigue is subjective, and the placebo effect could be strong.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fatigue multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon, 97207-2964, United States